{
    "nctId": "NCT00939770",
    "title": "Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma",
    "phase": "Phase Ib/II",
    "recruitment": "Completed",
    "therapies": [
        {
            "id": 706,
            "therapyName": "Crizotinib",
            "synonyms": null
        }
    ],
    "ageGroups": [
        "adult",
        "child"
    ],
    "gender": "both",
    "variantRequirements": "yes",
    "sponsors": "Children's Oncology Group",
    "updateDate": "05/17/2019",
    "indications": [
        {
            "id": 10000003,
            "name": "Advanced Solid Tumor",
            "source": "JAX"
        },
        {
            "id": 50744,
            "name": "anaplastic large cell lymphoma",
            "source": "DOID"
        },
        {
            "id": 3620,
            "name": "central nervous system cancer",
            "source": "DOID"
        },
        {
            "id": 769,
            "name": "neuroblastoma",
            "source": "DOID"
        }
    ],
    "variantRequirementDetails": [
        {
            "molecularProfile": {
                "id": 2446,
                "profileName": "ALK fusion"
            },
            "requirementType": "partial - required"
        },
        {
            "molecularProfile": {
                "id": 1267,
                "profileName": "ALK mutant"
            },
            "requirementType": "partial - required"
        },
        {
            "molecularProfile": {
                "id": 1760,
                "profileName": "ALK amp"
            },
            "requirementType": "partial - required"
        }
    ]
}